Pfizer Projects $10–15 Billion Annual Revenue from mRNA Vaccines by 2030

Intelligent Finance APP learned that Pfizer (PFE.US) said in an investor report on Monday that it expects its mRNA vaccine portfolio to generate annual revenue of $10 billion to $15 billion by 2030. This forecast has, to a certain extent, eased market concerns that the expected decline in demand for COVID-19 vaccines and patent expirations could severely impact its revenue. Thanks to strong global demand for its COVID-19 vaccine and oral medication Paxlovid, the company's revenue this year is expected to exceed $100 billion, more than double what it was before the pandemic.

In November, Pfizer raised its 2022 sales forecast for its COVID-19 vaccine by $2 billion to $34 billion. However, sales related to the pandemic are expected to decline significantly in the coming years. Pfizer also faces the expiration of patent protection for some of its top-selling drugs after 2025, such as Ibrance for cancer treatment and Xeljanz for arthritis.

Pfizer Chief Business Officer Angela Hwang said in an investor report that due to patent expirations, the company expects to lose approximately $17 billion in annual sales between 2025 and 2030.

The company has been heavily investing in its mRNA product pipeline and stated that the production capacity of its COVID-19 vaccine Comirnaty, co-developed with its German partner BioNTech SE (BNTX.US), positions it as a market leader, emphasizing its ability to provide other types of mRNA vaccines globally.

According to statistics from Refinitiv, analysts generally expect that revenue generated from COVID-19 vaccines will significantly decline starting from 2023. It is also projected that Pfizer's Comirnaty sales related to the pandemic will decrease to approximately $6.7 billion by 2027.

Pfizer did not provide sales forecasts for different types of mRNA vaccines but indicated that the sales of its Respiratory Syncytial Virus (RSV) candidate vaccine, which is scheduled to launch in 2023, may peak by 2027, potentially exceeding $2 billion.